|
Title
|
|
|
|
The effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease
| |
|
Author
|
|
|
|
| |
|
Institution/Organisation
|
|
|
|
Multi-Centre Renal Bone Disease
| |
|
Abstract
|
|
|
|
| Lanthanum carbonate (Fosrenol(TM), Shire Pharmaceuticals) is a novel treatment for hyperphosphataemia. In this open-label study, we compared the effects of lanthanum carbonate and calcium carbonate on bone in dialysis patients. Paired bone biopsies were taken, at baseline and after 1 year of treatment, in 33 lanthanum- and 30 calcium-treated patients. Serum phosphate levels were well controlled in both groups and lanthanum carbonate was well tolerated. After 1 year of lanthanum carbonate treatment, five of seven patients with low bone turnover at baseline and four of five with hyperparathyroidism developed a more normal bone turnover. Only one; lanthanum patient developed adynamic bone compared with six in the calcium group. Analyses of data so far indicate that lanthanum carbonate does not have any adverse effects on bone. |
| |
|
Language
|
|
|
|
English
| |
|
Source (book)
|
|
|
|
Proceedings 9th Asian Pacific Congress of Nephrology (16-20 February 2003)
| |
|
Publication
|
|
|
|
Bologna
:
Monduzzi
,
2003
| |
|
ISBN
|
|
|
|
88-323-3101-2
| |
|
Volume/pages
|
|
|
|
p. 191-194
| |
|
ISI
|
|
|
|
000182539200037
| |
|